387
Views
22
CrossRef citations to date
0
Altmetric
Original Research

Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC

, DMSc, , , , , & show all
Pages S3-S9 | Published online: 05 May 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

José A González-Masiá, Damián García-Olmo & Dolores C García-Olmo. (2013) Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. OncoTargets and Therapy 6, pages 819-832.
Read now

Articles from other publishers (21)

Fang-Qi Li & Jiu-Wei Cui. (2022) Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer. Critical Reviews in Oncology/Hematology 179, pages 103800.
Crossref
Estela Sánchez-Herrero, Roberto Serna-Blasco, Lucia Robado de Lope, Víctor González-Rumayor, Atocha Romero & Mariano Provencio. (2022) Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Frontiers in Oncology 12.
Crossref
Enrique Sanz-Garcia, Eric Zhao, Scott V. Bratman & Lillian L. Siu. (2022) Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. Science Advances 8:4.
Crossref
Misako Nagasaka, Mohammed Hafiz Uddin, Mohammed Najeeb Al-Hallak, Sarah Rahman, Suresh Balasubramanian, Ammar Sukari & Asfar S. Azmi. (2021) Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Molecular Cancer 20:1.
Crossref
Yuanyuan Lu & Li Li. (2021) The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis. Technology in Cancer Research & Treatment 20, pages 153303382110437.
Crossref
Elisa Gobbini, Aurélie Swalduz, Matteo Giaj Levra, Sandra Ortiz-Cuaran, Anne-Claire Toffart, Maurice Pérol, Denis Moro-Sibilot & Pierre Saintigny. (2020) Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. Cancers 12:11, pages 3112.
Crossref
Zhoumiao Chen, Huiwen Miao, Qingxin Zeng, Shaohua Xu, Zhao Chen & Kai Liu. (2020) Circulating cell-free DNA as a diagnostic and prognostic biomarker for non-small-cell lung cancer: a systematic review and meta-analysis. Biomarkers in Medicine 14:7, pages 587-597.
Crossref
Shanshan Ding, Xingguo Song, Xinran Geng, Lele Liu, Hongxin Ma, Xiujuan Wang, Ling Wei, Li Xie & Xianrang Song. (2019) Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer . Thoracic Cancer 10:10, pages 1973-1983.
Crossref
Katrin Brodbeck, Stefanie Kern, Sylvia Schick, Arnd Steinbrück, Michael Schwerer, Birgit Bayer, Katja Anslinger & Steffen Peldschus. (2018) Quantitative analysis of individual cell-free DNA concentration before and after penetrating trauma. International Journal of Legal Medicine 133:2, pages 385-393.
Crossref
Young Kwang Chae & Michael S. Oh. (2019) Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. Journal of Thoracic Oncology 14:1, pages 16-24.
Crossref
Shaoyi Leng, Jianjun Zheng, Yinhua Jin, Hongbin Zhang, Ya Zhu, Jing Wu, Yan Xu & Puhong Zhang. (2018) Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis. Clinica Chimica Acta 477, pages 160-165.
Crossref
Roberta Maltoni, Valentina Casadio, Sara Ravaioli, Flavia Foca, Maria Maddalena Tumedei, Samanta Salvi, Filippo Martignano, Daniele Calistri, Andrea Rocca, Alessio Schirone, Dino Amadori & Sara Bravaccini. (2017) Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer. Oncotarget 8:10, pages 16642-16649.
Crossref
Anne Winther-Larsen, Joan Fledelius, Christina Demuth, Catharina M Bylov, Peter Meldgaard & Boe S Sorensen. (2016) Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. Translational Oncology 9:6, pages 505-511.
Crossref
Bo Ai, Huiquan Liu, Yu Huang & Ping Peng. (2016) Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget 7:28, pages 44583-44595.
Crossref
Adam Szpechcinski, Piotr Rudzinski, Wlodzimierz Kupis, Renata Langfort, Tadeusz Orlowski & Joanna Chorostowska-Wynimko. (2016) Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer Letters 374:2, pages 202-207.
Crossref
C. Tissot, S. Villar, M. Olivier & S. Couraud. (2016) Int?r?ts de l?ADN circulant pour la prise en charge du cancer broncho-pulmonaire. Revue de Pneumologie Clinique 72:1, pages 61-71.
Crossref
XIAOLI LOU, YANQIANG HOU, DONGYU LIANG, LIANG PENG, HONGWEI CHEN, SHANYUAN MA & LURONG ZHANG. (2015) A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: Sensitivity and specificity for the diagnosis of myocardial infarction. International Journal of Molecular Medicine 35:1, pages 72-80.
Crossref
Kun Nie, Yujie Jia & Xuezhu Zhang. (2014) Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumor Biology 36:1, pages 7-19.
Crossref
Mary Jo Fackler, Zoila Lopez Bujanda, Christopher Umbricht, Wei Wen Teo, Soonweng Cho, Zhe Zhang, Kala Visvanathan, Stacie Jeter, Pedram Argani, Chenguang Wang, Jaclyn P. Lyman, Marina de Brot, James N. Ingle, Judy Boughey, Kandace McGuire, Tari A. King, Lisa A. Carey, Leslie Cope, Antonio C. Wolff & Saraswati Sukumar. (2014) Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. Cancer Research 74:8, pages 2160-2170.
Crossref
R. Almufti, M. Wilbaux, A. Oza, E. Henin, G. Freyer, M. Tod, O. Colomban & B. You. (2014) A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Annals of Oncology 25:1, pages 41-56.
Crossref
Paola Ulivi & Rosella Silvestrini. (2013) Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cellular Oncology 36:6, pages 439-448.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.